DE651434C - Method of preventing denaturation of protein medicinal products dissolved in water - Google Patents

Method of preventing denaturation of protein medicinal products dissolved in water

Info

Publication number
DE651434C
DE651434C DEI47557D DEI0047557D DE651434C DE 651434 C DE651434 C DE 651434C DE I47557 D DEI47557 D DE I47557D DE I0047557 D DEI0047557 D DE I0047557D DE 651434 C DE651434 C DE 651434C
Authority
DE
Germany
Prior art keywords
protein
water
medicinal products
products dissolved
preventing denaturation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DEI47557D
Other languages
German (de)
Inventor
Dr Max Bockmuehl
Eugen Doerzbach
Dr Erich Simons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IG Farbenindustrie AG
Original Assignee
IG Farbenindustrie AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IG Farbenindustrie AG filed Critical IG Farbenindustrie AG
Priority to DEI47557D priority Critical patent/DE651434C/en
Application granted granted Critical
Publication of DE651434C publication Critical patent/DE651434C/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Description

Verfahren zur Verhinderung der Denaturierung in Wasser gelöster eiweißhaltiger Heilmittel Bekanntlich zeigen eiweißhaltige Lösungen die Eigenschaft, . daß sie nicht dauernd klar bleiben, sondern zur Flockenbildung neigen, was auf Denaturierung des Eiweißes beruht. Dieser -Umstand macht sich besonders bei therapeutischen Präparaten störend bemerkbar.Process for preventing denaturation of proteinaceous substances dissolved in water Remedies It is well known that solutions containing protein show the property. that they do not stay clear all the time, but tend to form flakes, which indicates denaturation of protein is based. This circumstance is particularly evident with therapeutic preparations noticeably disturbing.

Es wurde nun gefunden, daß man die Denaturierung und damit die Flockung von eiweißhaltigen Lösungen aufheben oder weitgehend verhindern kann, indem man den eiweißhaltigen. Lösungen höhermolekulare Eiweißabbauprodukte, insbesondere Säuren, wie Protalbinsäure, Lysalbinsäure usw., zugibt. Insbesondere sind die Salze dieser Eiweißabbauprodukte, besonders die Alkalisalze, für das Verfahren geeignet. Man führt das Verfahren zweckmäßig so aus, daß man die erwähnten Stoffe den fertigen Lösungen zugibt. Mit gleichem Erfolge können die die Flockung verhindernden Stoffe auch in einer beliebigen Stufe des Fabrikationsproz es,ses der eiweißhaltigen Lösung zugesetzt werden.It has now been found that the denaturation and thus the flocculation of protein-containing solutions can be eliminated or largely prevented by the protein-rich. Solutions of high molecular weight protein degradation products, especially acids, such as protalbic acid, lysalbic acid, etc., adds. In particular, the salts are these Protein breakdown products, especially the alkali salts, are suitable for the process. Man expediently carries out the process in such a way that the substances mentioned are finished Admits solutions. The substances preventing flocculation can be equally successful also in any stage of the manufacturing process of the protein-containing solution can be added.

Es ist zwar bekannt, daß höhermolekuilare Eiweißabbauprodukte die Eigenschaften von Schutzkolloiden besitzen und beispielsweise die Fähigkeit haben, Sole von Metallkolloiden vor der Ausflockung zu schützen. Weiterhin ist es bekannt, in Wasser unlösliche oder schwer lösliche Eiweißverbindungen durch den Zusatz hydrotropisch wirkender Körper in wässerige Lösungen zu überführen. Die Möglichkeit, die Denaturierung von in wässeriger Lösung befindlichem Eiweiß durch den Zusatz von höhermolekularen Eiweißabbauprodukten zu verhindern, ist demgegenüber jedoch neu und überraschend. Beispiele i. Eine i %ige Thyreoglobulinlösung wird nach dem Zusatz eines Sterilisierungsmittels. mit i 0,'o protalbinsaurem Natrium unter Umrühren versetzt. Die Lösung zeigt nach dem Filtrieren keine Flockenbildung mehr.It is known that protein degradation products of higher molecular weight are the Have the properties of protective colloids and, for example, have the ability To protect brine from metal colloids from flocculation. It is also known Protein compounds that are insoluble or sparingly soluble in water due to the addition of hydrotropic to transfer the acting body into aqueous solutions. The possibility of denaturation of protein in aqueous solution through the addition of higher molecular weight However, preventing protein breakdown products is new and surprising. Examples i. A i% thyroglobulin solution is after the addition of a sterilizing agent. with i 0, 'o sodium protalbinate while stirring. The solution shows no more flocculation after filtering.

2. Eine fraktionierte Thyreoglobulinlösung wird auf die gewünschte Konzentration eingestellt und mit so viel protalbinsaurem Natrium versetzt, daß die Lösung i 0 o0 davon enthält. Die Lösung wird nunmehr mit Trikresol sterilisiert und durch Seitzfilter geklärt.2. A fractionated thyroglobulin solution is added to the desired Concentration adjusted and treated with so much protalbinate sodium that the solution contains i 0 o0 thereof. The solution is now sterilized with tricresol and clarified by Seitz filters.

3. Trockenpulver von Inselhormon wird nach dem Ergebnis der Standardisierung mit Alkalialbuminat vermischt und die Substanz allmählich in der berechneten Menge sauren Wassers aufgelöst, so daß eine an Alkali= albumin.at r°/QOige Lösung entsteht. Nach denn'-Filtrieren erhält man eine beständige, keine' Flocken bildende Lösung. ' _3. Dry powder of islet hormone is made according to the result of standardization with Alkali albuminate mixed and the substance gradually in the calculated amount of acidic water, so that an alkali = albumin.at r ° / QOige Solution emerges. After filtering, a consistent, no 'flake is obtained forming solution. '_

Claims (1)

1 PATENT ANSPRL, CH Verfahren zur Verhinderung der Denaturierung in Wasser gelöster eiweißhaltiger Heilmittel, gekennzeichnet durch einen Zusatz von höhermolekularen Eiweißabbauprodukten. 1 PATENT ANSPRL, CH Process to prevent denaturation of protein-containing medicinal products dissolved in water, characterized by the addition of higher-molecular protein degradation products.
DEI47557D 1933-07-09 1933-07-09 Method of preventing denaturation of protein medicinal products dissolved in water Expired DE651434C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DEI47557D DE651434C (en) 1933-07-09 1933-07-09 Method of preventing denaturation of protein medicinal products dissolved in water

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DEI47557D DE651434C (en) 1933-07-09 1933-07-09 Method of preventing denaturation of protein medicinal products dissolved in water

Publications (1)

Publication Number Publication Date
DE651434C true DE651434C (en) 1937-10-15

Family

ID=7192024

Family Applications (1)

Application Number Title Priority Date Filing Date
DEI47557D Expired DE651434C (en) 1933-07-09 1933-07-09 Method of preventing denaturation of protein medicinal products dissolved in water

Country Status (1)

Country Link
DE (1) DE651434C (en)

Similar Documents

Publication Publication Date Title
DE2433209A1 (en) HEAT-STABLE PLASMA PROTEIN SOLUTIONS, PROCESS FOR THEIR PRODUCTION AND MEDICINAL PREPARATIONS
DE651434C (en) Method of preventing denaturation of protein medicinal products dissolved in water
AT144185B (en) Process for the preparation of non-flocculent solutions of proteinaceous medicinal products.
DE657129C (en) Process for the production of solutions or extracts from bacteria, pollen or other plant cells
DE960579C (en) Process for the production of a heat-sterilizable adrenocorticotropin preparation
CH178361A (en) Process for the preparation of non-flocculent solutions of therapeutic products containing proteins.
DE712791C (en) Process for the preparation of solutions of the blood sugar lowering pancreatic hormone
DE750119C (en) Process for the production of protein substances from muscle fibers of animal origin
DE505062C (en) Process for the production of drugs for organ or. tissue-specific treatment of diseases of the human and animal body
AT157575B (en) Process for the production of undecomposed, sterilizable drug solutions from the double compound theophylline-piperazine.
DE464674C (en) Process for the preparation of products containing cholesterol which are colloidally soluble in an alkaline medium
DE629841C (en) Process for the preparation of an aqueous quinine solution for injection purposes
AT127981B (en) Process for the production of an irritant which promotes and regulates the central activities.
DE417973C (en) Process for the production of colloidal metal solutions
DE874061C (en) Process for the production of a blood-coagulant substance from the lungs
AT129490B (en) Process for obtaining the anterior pituitary lobe hormone, which is characterized by its development-promoting and stimulating effect on the gonads, in a pure state.
DE519320C (en) Process for the production of sulphobasic mercury compounds
AT124884B (en) Process for the production of hormone preparations.
DE531846C (en) Process for the production of physiologically active copper-arsenic compounds
DE680339C (en) Process for the production of plant extracts that remain clear
DE662835C (en) Process for the preparation of water-soluble laxatives
DE660780C (en) Pesticides
DE82951C (en)
DE415095C (en) Process for the production of a bismuth complex compound of the quinoline series which is readily soluble in water
DE555241C (en) Process for the preparation of amino-substituted guaiacolar acids and their reduction products